Provider of lead generation and optimisation services will perform chemical lead optimisation of compounds for biotech company
Asinex, a provider of lead generation and optimisation services, has announced a multi-FTE deal with biotech company Biovitrum to perform chemical lead optimisation of compounds discovered in Biovitrum's proprietary compound collection.
From initial starting points a number of interesting lead series have been developed by Biovitrum.
Rapid evaluation of these possibilities, with several rounds of optimisation has already been successfully completed, and options for further optimisation are being explored.
Charles Hedgecock, director of medicinal chemistry at Biovitrum said, "The flexibility Asinex provides in enabling us to access skilled synthetic chemists in support of some of our late stage projects, is important in maintaining momentum through to the clinic." Mikhail Kirpichenok, director of research at Asinex commented "We are delighted to be working with Biovitrum which is one of the leading biotech companies in Europe.
We are very pleased that Biovitrum recognises our expertise in providing lead optimization of the highest quality. We look forward to the successful completion of our ongoing projects and hope to continue to develop our collaboration in the future."
